There has been a recent interest in the development of novel small molecule compounds that target components of the clock (e.g., REV-ERB, ROR, and CRY) (24, 50, , –53), and these results open a potential new therapeutic avenue in the treatment of RA and other inflammatory conditions. The gene discussed is CRYL1; the disease is rheumatoid arthritis.